EMA Webinar Series – September 2022 EMA Webinar Series – September 2022 The European Medicines Agency (EMA) will be hosting a series of webinars in September... EMA Webinar Series – September 2022
EMA HMPC – Final Public Statement on Salvia miltiorrhiza Bunge, radix et rhizome EMA HMPC – Final Public Statement on Salvia miltiorrhiza Bunge, radix et rhizome The European Medicines Agency (EMA) Committee on... EMA HMPC – Final Public Statement on Salvia miltiorrhiza Bunge, radix et rhizome
Prolongation of Signal Detection in EudraVigilance Pilot EMA Prolongs Signal Detection in EudraVigilance Pilot The European Medicines Agency (EMA) has announced that the pilot of monitoring of... Prolongation of Signal Detection in EudraVigilance Pilot
EMA Reminder – Companies to Register their Industry Single Point of Contact (i-SPOC) on Supply and Availability EMA Reminder – Companies to Register their Industry Single Point of Contact (i-SPOC) on Supply and Availability EMA has issued... EMA Reminder – Companies to Register their Industry Single Point of Contact (i-SPOC) on Supply and Availability
MHRA – July 2022 Licensing Time-based Performance Measures Published MHRA – July 2022 Licensing Time-based Performance Measures Published MHRA publish data on the expected time taken to process and... MHRA – July 2022 Licensing Time-based Performance Measures Published
EMA HMPC Meeting Report – July 2022 EMA’s Committee on Herbal Medicinal Products (HMPC) has published the report from their July 2022 meeting EMA’s Committee on Herbal... EMA HMPC Meeting Report – July 2022
MHRA Publishes Marketing Authorisations Granted in July 2022 MHRA’s list of marketing authorisations granted in July 2022 MHRA granted two OTC licences in July 2022. Details of these... MHRA Publishes Marketing Authorisations Granted in July 2022
MHRA Public Assessment Report – Reclassification Application to Increase Pack Size of Nicorette QuickMist 1mg/spray mouthspray & Nicorette QuickMist smart track 1mg/spray mouthspray MHRA Public Assessment Report – Reclassification Application to Increase Pack Size of Nicorette QuickMist 1mg/spray mouthspray & Nicorette QuickMist smart... MHRA Public Assessment Report – Reclassification Application to Increase Pack Size of Nicorette QuickMist 1mg/spray mouthspray & Nicorette QuickMist smart track 1mg/spray mouthspray
MHRA Nitrosamines – Step 3 Deadline Extended MHRA Nitrosamines – Medicines Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing – Step 3... MHRA Nitrosamines – Step 3 Deadline Extended
MHRA Board Meeting – 20 September 2022 MHRA (Medicines and Healthcare products Regulatory Agency) Board Meeting – 20 September 2022 The MHRA Board will meet in public... MHRA Board Meeting – 20 September 2022
CMDh Workplan to 2025 – Published CMDh Workplan to 2025 – Published The Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) has published its... CMDh Workplan to 2025 – Published
MHRA Public Assessment Report – Reclassification of Sudafed Plus Blocked Nose 1mg/50mg/ml Nasal Spray Solution MHRA Public Assessment Report – Reclassification of Sudafed Plus Blocked Nose 1mg/50mg/ml Nasal Spray Solution MHRA has published the Public... MHRA Public Assessment Report – Reclassification of Sudafed Plus Blocked Nose 1mg/50mg/ml Nasal Spray Solution
